• PUK1 THE TIMELY CONSTRUCTION OF AN ARTERIOVENOUS FISTULAE- A KEY FACTOR IN REDUCING MORBIDITY AND MORTALITY AND IMPROVING ECONOMIC EFFECTIVENESS

    Nov 1, 2005, 00:00

  • PCV44 COST-EFFECTIVENESS OF ROSUVASTATIN IN THE PREVENTION OF ISCHEMIC HEART DISEASE IN PORTUGAL

    Nov 1, 2005, 00:00

  • CV3 A COST-EFFECTIVENESS ANALYSIS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE

    Nov 1, 2005, 00:00

  • PUK14 COST OF ILLNESS OF FEMALE LOWER URINARYTRACT SYMPTOMS (LUTS)

    Nov 1, 2005, 00:00

  • POS9 EXTENDING THE BURDEN OF DISEASE PROTOCOL- DERIVING DISABILITY WEIGHTS FOR RISK FACTOR DISEASES—THE CASE FOR OSTEOPOROSIS

    Nov 1, 2005, 00:00

  • Assessing Patient Satisfaction- Concepts, Applications, and Measurement

    Nov 1, 2005, 00:00

  • PMC16 THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM (NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH REGISTRY

    Nov 1, 2005, 00:00

  • PHP39 PUBLIC FUNDING OF DRUGS FOR ORPHAN DISEASES

    Nov 1, 2005, 00:00

  • PFM1 FIBROMYALGIA SYNDROME- A PORTUGUESE EPIDEMIOLOGICAL SURVEY

    Nov 1, 2005, 00:00

  • PMH48 QUALITY OF LIFE IN MAJOR DEPRESSION- RESULTS OF THE MC3 TRIAL

    Nov 1, 2005, 00:00

  • Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective

    Nov 1, 2005, 00:00

  • PSN9 PATTERNS OF TOPICAL ACNE PRESCRIPTION MEDICATION USE- ANALYSIS OF A LARGE-SCALE RETROSPECTIVE CLAIMS DATABASE

    Nov 1, 2005, 00:00

  • PHP31 CHARGES FOR HOSPITAL ADMISSIONS ATTRIBUTABLE TO HEALTH DISPARITIES FOR AFRICAN AMERICAN PATIENTS IN SOUTH CAROLINA DURING 1998-2002

    Nov 1, 2005, 00:00

  • PDB22 ASSESSING THE EFFICIENCY OF USING CONTINUOUS SUBCUTANEOUS INSULIN-INFUSION (CSII) VERSUS MULTIPLE DAILY INJECTIONS (MDI) IN SPANISH DIABETES MELLITUSTYPE-I (DM I) PATIENTS. COST—EFFECTIVENESS ANALYSIS

    Nov 1, 2005, 00:00

  • PDB29 HEALTH ECONOMIC EVALUATION OF INSULIN GLARGINE FOR THE TREATMENT OF TYPE-1 AND TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • CV1 ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME

    Nov 1, 2005, 00:00

  • PAR17 BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY

    Nov 1, 2005, 00:00

  • PHP5 COST OF SEVERE BLUNT TRAUMA IN THE UK

    Nov 1, 2005, 00:00

  • PMH38 A DISCRETE EVENT SIMULATION (DES) MODEL TO DESCRIBE SCHIZOPHRENIA

    Nov 1, 2005, 00:00

  • PCV57 COST-EFFECTIVENESS OF NEBIVOLOL VERSUS ATENOLOL AND ACE INHIBITOR MONOTHERAPY IN PATIENTS WITH MODERATE HYPERTENSION

    Nov 1, 2005, 00:00

  • PHP2 IMPLEMENTATION OF AN EVIDENCE BASED GUIDELINE FOR CLINICAL NUTRITION IN A 500 BED HOSPITAL IN NORTHERN GERMANY- INFLUENCE ON DIRECT COST FOR CLINICAL NUTRITION

    Nov 1, 2005, 00:00

  • PCV23 ECONOMIC EVALUATION OFVALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE IN THE HUNGARIAN HEALTH CARE SETTING

    Nov 1, 2005, 00:00

  • PED2 LONG-TERM QUALITY OF LIFE (QOL) OUTCOMES IN THE TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY (GHD)—A 5 YEAR STUDY

    Nov 1, 2005, 00:00

  • PCV84 SURGICAL TREATMENT OF ABDOMINAL AORTIC ANEURISM- ANALYSIS OF OPERATING COSTS. ENDOVASCULAR TREATMENT VERSUS TRADITIONAL SURGERY

    Nov 1, 2005, 00:00

  • PGI2 COST EFFECTIVENESS AND BUDGET IMPACT OF LAMIVUDINE ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS TYPE B PATIENTS IN TAIWAN

    Nov 1, 2005, 00:00

  • PMH20 RELATION BETWEEN SYMPTOMS IN SCHIZOPHRENIA AND RISK OF HARM TO SELF AND OTHERS

    Nov 1, 2005, 00:00

  • PIH7 QUALITY OF LIFE OF ITALIAN GENERAL POPULATION AGED 40 TO 79 YEARS OLD

    Nov 1, 2005, 00:00

  • PDB18 COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA- A UK PERSPECTIVE

    Nov 1, 2005, 00:00

  • PUK31 DEVELOPMENT AND PILOT TESTING OF A NEW SCALE SPECIFICALLY MEASURING THE IMPACT OF STRESS URINARY INCONTINENCE (SUI) ON COMMON PHYSICAL ACTIVITIES OF DAILY LIFE

    Nov 1, 2005, 00:00

  • PCN17 THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN FORTHE TREATMENT OF PATIENTS WITH EGFR-EXPRESSING METASTATIC COLORECTAL CANCER AFTER FAILURE OF IRINOTECAN-INCLUDING CYTOTOXIC THERAPY IN SCOTLAND

    Nov 1, 2005, 00:00

  • PUK9 COST-EFFECTIVENESS OF PARICALCITOL IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM- THE EXPERIENCE IN ITALY

    Nov 1, 2005, 00:00

  • CN4 COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER

    Nov 1, 2005, 00:00

  • POB9 EVALUATION OF THE ASSOCIATION BETWEEN BODY MASS INDEX, WAIST CIRCUMFERENCE AND HEALTH-RELATED UTILITY (EQ5D)

    Nov 1, 2005, 00:00

  • PIN9 A COST UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A (40 KD) VERSUS PEGINTERFERON ALFA-2B (I2KD) FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN THE UK

    Nov 1, 2005, 00:00

  • PMC10 A METHODOLOGICAL APPROACH TO ASSESS COST DATA IN THE CONTEXT OF A DECISION ANALYTIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF THE METABOLIC SYNDROME

    Nov 1, 2005, 00:00

  • PCV86 THE ECONOMIC BURDEN OF EXPERIENCING MAJOR COMPLICATIONS DURING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2005, 00:00

  • PCN16 ADDING RITUXIMABTO STANDARD CHEMOTHERAPY APPEARS DOMINANT VS. CHEMOTHERAPY ALONE IN ADVANCED STAGE NHL—INTERIM RESULTS FROM A RANDOMIZED CLINICAL TRIAL (RCT)

    Nov 1, 2005, 00:00

  • POS10 PERSISTENCE OF DRUG TREATMENT WITH ALENDRONATE AND RISEDRONATE IN PRIMARY CARE PATIENTS

    Nov 1, 2005, 00:00

  • PHP25 USING AN ITALIAN POPULATION DATABASE TO PROFILE PREVALENCE AND COSTS OF CHRONIC CONDITIONS

    Nov 1, 2005, 00:00

  • PDB14 COST OF DIABETES MELLITUS TYPE-2 AND SELF MEASUREMENT OF BLOOD GLUCOSE IN GERMANY- A HEALTH INSURANCE PERSPECTIVE

    Nov 1, 2005, 00:00

  • PUK10 COST-EFFECTIVENESS OF MIMPARAAMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL

    Nov 1, 2005, 00:00

  • PED4 SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • MC5 ON EVALUATING COST ASSOCIATED WITH EVENT-CENSORED DATA APPLICATION TO ALL-CAUSE GRAFT FAILURE FOLLOWING KIDNEYTRANSPLANTATION

    Nov 1, 2005, 00:00

  • PSN10 THE RISE OF THE GENERIC DRUG MARKET- IMPLICATIONS FOR THE TREATMENT OF SKIN DISEASES

    Nov 1, 2005, 00:00

  • PEY14 IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY

    Nov 1, 2005, 00:00

  • PHP41 EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE REIMBURSEMENT AGENCIES IN SWEDEN AND FINLAND—A CROSS COUNTRY COMPARISON

    Nov 1, 2005, 00:00

  • PCN34 COST-EFFECTIVENESS OF ANASTROZOLE OVERTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE- THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL

    Nov 1, 2005, 00:00

  • PCV30 CLOPIDOGREL LOADING DOSE AND CARDIOVASCULAR OUTCOMES IN ACUTE CORONARY SYNDROME PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2005, 00:00

  • PCN26 CUTANEOUS CANCER TREATMENT AND COSTS IN GERMANY

    Nov 1, 2005, 00:00

  • PDB6 REDUCTION IN DIABETES DRUGS USE AND DRUG COSTS IN OBESE PEOPLE TREATED WITH ORLISTAT

    Nov 1, 2005, 00:00

  • PUK17 BENIGN PROSTATIC HYPERPLASIA- CROSS EVALUATION OF THE GP-PATIENT IPSS

    Nov 1, 2005, 00:00

  • PRS12 THE BURDEN OF LUNG DISEASE (BOLD) ECONOMIC MODEL

    Nov 1, 2005, 00:00

  • PCN35 A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)

    Nov 1, 2005, 00:00

  • PDB57 TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGYWITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES- THE CANADIAN INSIGHT STUDY

    Nov 1, 2005, 00:00

  • CO3 META-REGRESSION ASSESSMENT OF ATOMOXETINE EFFICACY USING RANDOMIZED CONTROLLED ADHD TRIALS

    Nov 1, 2005, 00:00

  • PIH10 COST-EFFECTIVENESS STUDY OF ASSISTED REPRODUCTIVE TECHNIQUES IN SPAIN

    Nov 1, 2005, 00:00

  • PPN8 THE MOS-SHORT-FORM-12 (SF-12) AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN NEUROPATHIC PAIN (NEP) PATIENTS- RELIABILITY, CONCURRENT AND DISCRIMINANT VALIDITY

    Nov 1, 2005, 00:00

  • PDB44 USE OF ACETYL-SALICYLIC ACID FOR CARDIOVASCULAR PREVENTION IN PRIMARY CARE PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2005, 00:00

  • PCN1 ECONOMIC IMPACT OF ADOPTING PEMETREXED PLUS CISPLATIN FOR MALIGNANT PLEURAL MESOTHELIOMA INTO SCOTTISH CLINICAL PRACTICE

    Nov 1, 2005, 00:00

  • PRS19 IMPACT OF DYSPNOEA ON DAILY ACTIVITIES IN COPD PATIENTS—DEVELOPMENT AND TESTING OF A NEW QUESTIONNAIRE FOR CLINICAL PRACTICE AND CLINICAL TRIALS

    Nov 1, 2005, 00:00

  • PUK7 DELIVERING TREATMENT EFFECTIVENESS- COSTS AND PERSISTENCE OF TOLTERODINE IN THE MANAGEMENT OF OAB IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PMH41 REMISSION CRITERIA FOR DEPRESSION WHEN USING SHORT VERSIONS OF THE HAMILTON DEPRESSION RATING SCALE (HDRS)

    Nov 1, 2005, 00:00

  • PNL9 COST-EFFECTIVENESS OF ALTERNATIVE POLIO IMMUNIZATION POLICIES IN SOUTH AFRICA

    Nov 1, 2005, 00:00

  • PHP21 PHARMACEUTICAL POLICY IN GREECE- RECENT DEVELOPMENTS AND THE ROLE OF PHARMACOECONOMICS

    Nov 1, 2005, 00:00

  • PST6 FACTORS RELATED TO LONGER HOSPITAL STAY AFTER FIRST-EVER ISCHEMIC STROKE

    Nov 1, 2005, 00:00

  • PIN17 COST-EFFECTIVENESS ANALYSIS OF ENFUVIRTIDE ADDED TO AN OPTIMISED THERAPYVS. AN OPTIMISED THERAPY ALONE IN PATIENTS WITH H.I.V/AIDS

    Nov 1, 2005, 00:00

  • MC1 USE OF A MODIFIED RECURSIVE PARTITIONING AND AMALGAMATION (RECPAM)TECHNIQUE IN OUTCOMES RESEARCH

    Nov 1, 2005, 00:00

  • PMC20 INDIRECT COMPARISON (OR COMMON-COMPARATOR) METHODS FOR META-ANALYSIS OF SUMMARY DATA

    Nov 1, 2005, 00:00

  • PIH4 WHAT METHODS OF ASSESSMENT AND MANAGEMENT OF ELDERLY PEOPLE ARE COST EFFECTIVE

    Nov 1, 2005, 00:00

  • PCV21 COST EFFECTIVENESS ANALYSIS OF BISOPROLOL TREATMENT FOR HEART FAILURE

    Nov 1, 2005, 00:00

  • Hierarchical Construct Validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among Outpatient Pharmacy Consumers

    Nov 1, 2005, 00:00

  • PCN24 ESTIMATING THE COST OF INFORMAL CAREGIVING IN LUNG CANCER PATIENTS.THE HABIT STUDY

    Nov 1, 2005, 00:00

  • The Validation of Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue—The BSW

    Nov 1, 2005, 00:00

  • PIN6 INFECTIONS CAUSED BY RESISTANT CANDIDA SPECIES- COST-MINIMIZATION ANALISYS OF ANTIFUNGALTHERAPY IN BRAZIL

    Nov 1, 2005, 00:00

  • PCV6 IMPACT OF STATIN THERAPY INTENSITY ON ALL-CAUSE MORTALITY FOLLOWING CARDIOVASCULAR HOSPITALIZATION IN A MANAGED CARE POPULATION

    Nov 1, 2005, 00:00

  • PMH21 TREATMENT PERSISTENCE- A COMPARISON AMONG PATIENTS WITH SCHIZOPHRENIA WHO WERE INITIATED ON ATYPICAL ANTIPSYCHOTIC AGENTS

    Nov 1, 2005, 00:00

  • PEY3 INTRA-OCULAR PRESSURE (IOP) CONTROL OF LATANOPROST AND TRAVOPROST MONOTHERAPY IN DAILY PRACTICE

    Nov 1, 2005, 00:00

  • PRS1 CLINICAL AND TREATMENT FACTORS INFLUENCING THE OUTCOME OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS- LESSONS FOR FURTHER CLINICAL AND OUTCOMES RESEARCH

    Nov 1, 2005, 00:00

  • PHP19 PRESCRIPTION DRUGS AND ANNUAL BENEFIT CAPS—DO PATIENTS ANTICIPATE EXCEEDING THE CAP?

    Nov 1, 2005, 00:00

  • PCV89 COST-EFFECTIVENESS OF AN EXTENDED FOUR-WEEK FONDAPARINUX PROPHYLAXIS REGIMEN FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY

    Nov 1, 2005, 00:00

  • QL2 TESTING THE CROSS-WALK- SALVAGING CANCER SPECIFIC MEASURES FOR USE IN ECONOMIC EVALUATION

    Nov 1, 2005, 00:00

  • PDB45 PREDICTORS OF DIABETES MEDICATION UTILIZATION AND HEALTH CARE COSTS IN U.S. PATIENTS WITH TYPE-2 DIABETES- RESULTS FROM A NATIONAL SURVEY STUDY

    Nov 1, 2005, 00:00

  • PCV53 PATIENT PROFILE AND STATINS EFFECTIVENESS IN USUAL CARE

    Nov 1, 2005, 00:00

  • PDB28 COST-EFFECTIVENESS ANALYSES OF BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR + HUMAN SOLUBLE INSULIN VERSUS NEUTRAL PROTAMINE HAGEDORM + HUMAN SOLUBLE INSULIN REGIMENS IN GERMANY

    Nov 1, 2005, 00:00

  • IC2 PREDICTING THE COST-EFFECTIVENESS OFTHEABT-578 COATED DRIVER CORONARY STENT (ENDEAVOR) IN DE NOVO NATIVE CORONARY ARTERY LESIONS

    Nov 1, 2005, 00:00

  • PCV29 USE OF CONTRAST ECHOCARDIOGRAPHY- A REVIEW OF CLINICAL DATA USING A SYSTEMATIC APPROACH

    Nov 1, 2005, 00:00

  • PEY11 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION- COMPARING EARLY AND LATE MACUGEN TREATMENT

    Nov 1, 2005, 00:00

  • PO4 ESTIMATING QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS ORTOXICITY USING A MULTIVARIATE FAILURE TIME REGRESSION MODEL

    Nov 1, 2005, 00:00

  • PCV79 POSTMYOCARDIAL INFARCTION CARDIAC REHABILITATION IN LOW RISK PATIENTS. RESULTS WITH A COORDINATED PROGRAM OF CARDIOLOGICAL AND PRIMARY CARE

    Nov 1, 2005, 00:00

  • PDB19 ECONOMIC EVALUATION OF SWITCHING TYPE-1 DIABETES PATIENTS FROM LONG-ACTING INSULIN GLARGINE INA BASAL/BOLUS REGIMEN TO LONG-ACTING INSULIN DETEMIR IN AN AUSTRIAN SETTING

    Nov 1, 2005, 00:00

  • PSN21 IMPACT OF CORTICOSTEROID-SPARING EFFECT OF AN EMOLLIENT MILK ON FAMILY'S QUALITY OF LIFE OF INFANTS AFFECTED BYATOPIC DERMATITIS

    Nov 1, 2005, 00:00

  • PIN20 STUDYVALIDATION OF QUALITY OF LIFE QUESTIONNAIRE MINI-HIV

    Nov 1, 2005, 00:00

  • HP1 IDENTIFYING PREDICTORS OF OFF-LABEL UTILIZATION PATTERNS OF TWO BIOTECHNOLOGY DRUGS, RECOMBINANT ERYTHROPOIETIN ALFA AND DARBEPOETIN ALFA A MULTI-HOSPITAL STUDY

    Nov 1, 2005, 00:00

  • PAR11 VALIDITY STUDIES AND SATISFACTION THRESHOLD OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)

    Nov 1, 2005, 00:00

  • PMD1 COST ANALYSIS OF MANAGEMENT STRATEGIES FOR CLOSED AND OPEN GRADE ITIBIAL SHAFT FRACTURES

    Nov 1, 2005, 00:00

  • PCV61 THE FRENCH CV@GOAL EDUCATIONAL PROGRAM FOR IMPROVING HBP MANAGEMENT BY PATIENTSAND PHYSICIANS- ASSESSMENT OF ITS IMPACT ON PATIENT'S KNOWLEDGE AND PATIENT-PHYSICIAN RELATIONSHIP

    Nov 1, 2005, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2005, 00:00

  • POB4 COST-OF-ILLNESS ANALYSIS OF JUVENILE OBESITY AND OF CO-MORBIDITYTYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY

    Nov 1, 2005, 00:00

  • Abstracts Index

    Nov 1, 2005, 00:00

  • PHP9 PHARMACEUTICAL CARE IN GREECE- A CITIZEN SATISFACTION SURVEY

    Nov 1, 2005, 00:00

  • PUK25 SPANISH RESEARCH NETWORK ON TRANSPLANTATION- THE SPANISH VERSION OF THE END-STAGE RENAL DISEASE SYMPTOM CHECK-LIST, A USEFUL TOOL FOR EVALUATE THE PERCEIVED HEALTH STATUS OF RENAL TRANSPLANT BEARERS

    Nov 1, 2005, 00:00

  • PAS1 COMPARISON OF TREATMENT WITH BUDESONIDE/FORMOTEROL (BUD/FM) PLUS BUD/FM PRN AS SINGLE INHALERTREATMENT VERSUS REGULAR BUD AND FM PLUS FM PRN AS MONOPRODUCTS IN PATIENTS WITH ASTHMA IN GREECE

    Nov 1, 2005, 00:00

  • PCN10 THE COST-EFFECTIVENESS OF POST-OPERATIVE RADIOTHERAPY AFTER BREAST CONSERVATION SURGERY IN STAGEI-II BREAST CANCER IN SWEDEN

    Nov 1, 2005, 00:00

  • PED3 A PROSPECTIVE REAL-LIFE STUDY OF QUALITY OF LIFE IN PATIENTS WITH ACROMEGALY

    Nov 1, 2005, 00:00

  • PSN14 CHANGES IN FUNCTIONAL ABILITY AS MEASURED BY DLQI IS CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB

    Nov 1, 2005, 00:00

  • PEY17 MODELING TREATMENTS FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE RELATED MACULAR DEGENERATION- COST-EFFECTIVENESS METHODS

    Nov 1, 2005, 00:00

  • PO3 CLASSIFYING AND PREDICTING ANTIPSYCHOTIC ADHERENCE AMONG SCHIZOPHRENIA OUTPATIENTS IN EUROPE- A LATENT CLASS ANALYSIS

    Nov 1, 2005, 00:00

  • PAR18 PATIENT COMPLIANCE IN THE TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGIC DMARDS AND PREDICTING FACTORS- A LITERATURE REVIEW

    Nov 1, 2005, 00:00

  • PCN18 LETROZOLE (FEMARA) IS A COST-EFFECTIVE TREATMENT IN THE EXTENDED ADJUVANT SETTING IN WOMEN WITH EARLY BREAST CANCER- AN APPLICATION TO CANADA

    Nov 1, 2005, 00:00

  • PDB50 MODELLING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN ABDOMINALLY OBESE PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PRS14 HEALTH CARE RESOURCES UTILIZATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACCORDING TO THEIR SEVERITY IN SPAIN

    Nov 1, 2005, 00:00

  • PCN28 DOCUMENTATION OF PHARMACY COST IN THE PREPARATION OF CHEMOTHERAPY INFUSIONS IN ACADEMIC AND COMMUNITY-BASED ONCOLOGY PRACTICES

    Nov 1, 2005, 00:00

  • PCV78 THE DIRECT COSTS OF SELECTED CARDIOVASCULAR DISEASES IN AUSTRIA

    Nov 1, 2005, 00:00

  • PCV64 HEALTH CARE UTILIZATION OF ANTIHYPERTENSIVE MEDICATION WITHIN THE SLOVAK REPUBLIC

    Nov 1, 2005, 00:00

  • PSN20 VALIDATION OF THE ITALIAN VERSION OF THE DERMATOLOGY LIFE QUALITY INDEX

    Nov 1, 2005, 00:00

  • PCV48 ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN) IN SPAIN

    Nov 1, 2005, 00:00

  • PDB52 TYPE-2 DIABETES MODELS THAT DO NOT ACCOUNT FOR MICROVASCULAR DISEASE SCREENING RATESAND IMPORTANT CONCOMITANT MEDICATION USE MAY LEAD TO SUBSTANTIAL MISREPRESENTATION OF THE COST-EFFECTIVENESS OF NEW MEDICATIONS

    Nov 1, 2005, 00:00

  • PSU8 APPLICATION OF (PRO)SPECTIVE STUDY OF PATIENT SATISFACTION (PS) TO MONITOR QUALITY AND TO SUPPORT MANAGEMENT OF HEALTH CARE PROVIDER—AN EXAMPLE OF MEETING ISO 9001-2000 REQUIREMENTS BY THE CARDIOSURGICAL UNIT IN POLAND.

    Nov 1, 2005, 00:00

  • PHP26 ADHERENCE INDEX OF PERFORMANCE—A NEW METHOD AND TOOL FOR ONGOING EVALUATION OF MEDICATION ADHERENCE IMPROVEMENT INITIATIVES

    Nov 1, 2005, 00:00

  • PDB56 AN ASSESSMENT OF THE LONG-TERM OUTCOME FOR LIRAGLUTIDE+METFORMIN VERSUS METFORMIN AND VERSUS METFORMIN+GLIMEPIRIDE INTYPE-2 PATIENTS WITH INADE-QUATE GLYCAEMIC CONTROL

    Nov 1, 2005, 00:00

  • PHP24 A SYSTEMATIC REVIEW OF THE EUROPEAN PHARMACEUTICAL MARKET AND THE IMPACT OF EUROPEAN UNION REGULATION AND JURISDICTION

    Nov 1, 2005, 00:00

  • POS1 SYSTEMATIC REVIEW OF IBANDRONATE FOR POSTMENOPAUSAL OSTEOPOROSIS

    Nov 1, 2005, 00:00

  • PEY20 IMPACT OF BEST AND WORST EYE VISUAL ACUITY ON VISION-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND UTILITY IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2005, 00:00

  • PEY7 NUMBER OF TREATABLE EYES WITH WET SUB-FOVEAL AGE-RELATED MACULAR DEGENARATION (ARMD) - USE OF DIRECT STANDARDIZATION AND MARKOV MODEL

    Nov 1, 2005, 00:00

  • PR4 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT)- A CONJOINT ANALYSIS EXERCISE

    Nov 1, 2005, 00:00

  • Impact of Computer-Generated Personalized Goals on Cholesterol Lowering

    Nov 1, 2005, 00:00

  • PNL15 PREFERENCE FOR RECONSTRUCTIVE INTERVENTIONS OF THE UPPER EXTREMITIES IN TETRAPLEGIA- THE IMPACT OF TREATMENT CHARACTERISTICS

    Nov 1, 2005, 00:00

  • POB8 VALIDITY OF DATA COLLECTED FROM AN INTERNET-BASED COHORT STUDY

    Nov 1, 2005, 00:00

  • PDB10 TYPE-2 DIABETES IN GERMANY- PREVALENCE AND MEDICATION USE

    Nov 1, 2005, 00:00

  • PNL16 THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY

    Nov 1, 2005, 00:00

  • PDB38 ANALYSIS OF THE COST OF DIABETES TREATMENT IN BULGARIA

    Nov 1, 2005, 00:00

  • PCV68 COST-EFFECTIVENESS OF RAISING HDL-CWITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH PERSISTENT DYSLIPIDEMIA IN AUSTRIAN, SWEDISH AND NORWEGIAN SETTINGS

    Nov 1, 2005, 00:00

  • PHP6 DRUG PRICE INDICES 1980-2004 IN FINLAND

    Nov 1, 2005, 00:00

  • PEY16 THE PREVALENCE AND COST OF TREATMENT OF PATIENTS TAKING ANTIGLAUCOMA AGENTS FOR GLAUCOMA OR OCULAR HYPERTENSION IN FRANCE

    Nov 1, 2005, 00:00

  • PFM2 FIBROMYALGIA SYNDROME- AN ITALIAN EPIDEMIOLOGICAL SURVEY

    Nov 1, 2005, 00:00

  • PCV17 VKA TREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION- COST DATA FROM THE INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT (ISAM)

    Nov 1, 2005, 00:00

  • PIN1 ASSESSING THE EXTERNAL VALIDITY OF DROTRECOGIN ALFA (ACTIVATED) CLINICAL TRIALS IN AN OBSERVATIONAL STUDY USING PROPENSITY SCORE MATCHING TO REDUCE RECRUITMENT BIAS

    Nov 1, 2005, 00:00

  • PST11 THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH CARE. DOES METHOD USED INFLUENCE OUTCOME?

    Nov 1, 2005, 00:00

  • PNL18 COST-EFFECTIVENESS OF CONTINUOUS DUODENAL DELIVERY OF LEVODOPA (DUODOPA®) IN PATIENTS WITH SEVERE PARKINSON'S DISEASE

    Nov 1, 2005, 00:00

  • PNL4 THE SOCIAL AND ECONOMIC BURDEN OF PAEDIATRIC EPILEPSY IN IRELAND- A PROSPECTIVE STUDY

    Nov 1, 2005, 00:00

  • PCV70 THE COSTS OF METABOLIC SYNDROME

    Nov 1, 2005, 00:00

  • PRS6 ECONOMIC EVALUATION OF TIOTROPIUM AND SALMETEROL IN THE TREATMENT OF COPD IN GREECE

    Nov 1, 2005, 00:00

  • PSN3 ECONOMIC EVALUATION OF PIMECROLIMUS, A NEW TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS IN HUNGARY

    Nov 1, 2005, 00:00

  • PHP18 GEOGRAPHICAL INFORMATION SYSTEM (GIS) ANALYSIS OF SMALL AREA INEQUALITIES IN DRUG EXPENDITURES IN HUNGARY

    Nov 1, 2005, 00:00

  • PIN8 INCREASED MANAGEMENT NEEDS AND CARE COSTS FOR NURSING HOME RESIDENTS WITH CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA

    Nov 1, 2005, 00:00

  • PUK4 BUDGET IMPACT ANALYSIS OF MIMPARAAMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL

    Nov 1, 2005, 00:00

  • PSN7 EPIDEMIOLOGY AND MANAGEMENT OF EXTERNAL GENITAL WARTS (EGW) IN FRANCE

    Nov 1, 2005, 00:00

  • PMH15 GALANTAMINE REDUCES CAREGIVER BURDEN- RESULTS FROM A NATURALISTIC STUDY

    Nov 1, 2005, 00:00

  • PDB5 IMPROVED TREATMENT SATISFACTION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE OR INSULIN GLARGINE

    Nov 1, 2005, 00:00

  • PMH50 DEVELOPMENT OF A COMPREHENSIVE EMOTIONAL, SOMATIC AND PAINFUL PHYSICAL SYMPTOMS CHECKLIST IN DEPRESSION IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PCN48 QUALITY OF LIFE AND RESOURCE UTILIZATION OF PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER- A CANADIAN PERSPECTIVE

    Nov 1, 2005, 00:00

  • PDB35 THE COST OF DIABETES MELLITUS IN SPAIN

    Nov 1, 2005, 00:00

  • PCV85 CLINICAL OUTCOME AND COST-EFFECTIVENESS OF DIFFERENT BYPASS MATERIALS IN VASCULAR SURGERY

    Nov 1, 2005, 00:00

  • HP3 PHYSICIAN PRESCRIBING OF SLEEP DISORDER MEDICATIONS IN UNITED STATES OUTPATIENT SETTINGS- FACTORS AFFECTING PRESCRIPTION OF HIGH ABUSE POTENTIAL AND COSTLY MEDICATIONS

    Nov 1, 2005, 00:00

  • PCV72 UTILIZATION PATTERNS OF ASPIRIN AMONG NSAID TREATED SUBJECTS WITH VARYING CARDIOVASCULAR RISK PROFILES IN A HEALTH BENEFITS POPULATION

    Nov 1, 2005, 00:00

  • PFM5 CROSS-SURVEY OF FRENCH AND PORTUGUESE RHEUMATOLOGISTS GLOBAL MANAGEMENT OF FIBROMYALGIA

    Nov 1, 2005, 00:00

  • PEY9 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION- COMPARING MACUGEN TO VISUDYNE

    Nov 1, 2005, 00:00

  • POS14 ELICITING AND QUANTIFYING PATIENT PREFERENCES FOR DOSING FREQUENCY

    Nov 1, 2005, 00:00

  • IN1 COSTS ASSOCIATED WITH SHORTER DURATION OF ANTIBIOTIC THERAPY IN HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA

    Nov 1, 2005, 00:00

  • PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

    Nov 1, 2005, 00:00

  • PSN1 USING THE GENERAL PRACTICE RESEARCH DATABASE TO ESTIMATE THE INCIDENCE, PREVALENCE AND MANAGEMENT OF HYPERHIDROSIS IN THE UK

    Nov 1, 2005, 00:00

  • PDB30 COST-EFFECTIVENESS OF PREVENTIVE INTERVENTIONS IN DIABETES MELLITUS AND ITS (MACROVASCULAR)COMPLICATIONS- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2005, 00:00

  • PAR7 HEALTH CARE UTILIZATION AND EXPENDITURE OF TWO PROGRAMS FOR OSTEOARTHRITIS OF THE KNEE AND HIP- ASSESSMENT AND IMPACT IN REAL-LIFE CONDITIONS

    Nov 1, 2005, 00:00

  • PCV38 THIENOPYRIDINE THERAPY IN ACUTE CORONARY SYNDROME PATIENTS RESIDING IN GERMANY

    Nov 1, 2005, 00:00

  • PCV71 COST-EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH GENERIC SIMVASTATIN IN THE UK NHS

    Nov 1, 2005, 00:00

  • PDB32 ECONOMIC EVALUATION OF THE LAPTOP-STUDY RESULTS

    Nov 1, 2005, 00:00

  • PNL1 EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV MODEL ESTIMATING THE COST EFFECTIVENESS OF MEMANTINE VERSUS STANDARD CARE IN ALZHEIMER DISEASE FROM A UK PERSPECTIVE

    Nov 1, 2005, 00:00

  • PAL1 DETERMINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE FORTHE ESPRINT-15 QUESTIONNAIRE FOR PATIENTS WITH ALLERGIC RINHITIS

    Nov 1, 2005, 00:00

  • MC3 METAMODELLING FORTHE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS

    Nov 1, 2005, 00:00

  • PNL13 IMPLANTABLE SYSTEMS PERFORMANCE REGISTRY (ISPR) A MEDICAL DEVICE AND PATIENT REGISTRY

    Nov 1, 2005, 00:00

  • PUK8 COST-EFFECTIVENESS OF SCREENING FOR ALBUMINURIA AND SUBSEQUENT TREATMENT WITH AN ACE-INHIBITOR; A PHARMACO-ECONOMIC ANALYSIS

    Nov 1, 2005, 00:00

  • PRS8 COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE NASAL DROPS VERSUS SURGICAL TREATMENT FOR NASAL POLYPOSIS IN POLAND

    Nov 1, 2005, 00:00

  • PMC21 EVALUATING THE DIFFERENCE BETWEEN AVERAGE WHOLESALE PRICE AND WHOLESALE ACQUISITION COST FOR PHARMACEUTICALS IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PSU2 COST-EFFECTIVENESS OF TWO REGIMENS OF TOTAL INTRAVENOUS ANESTHESIA USING INFUSION PUMP IN MEXICO

    Nov 1, 2005, 00:00

  • PRS4 INHALED CORTICOSTEROIDS AND BROCHODILATORS FOR SEVERE AND VERY SEVERE COPD PATIENTS- COST-EFFECTIVENESS AND HEALTH CARE BUDGET IMPACT IN ITALY

    Nov 1, 2005, 00:00

  • PGI16 GASTROESOPHAGEAL REFLUX DISEASE (GERD) — PREVALENCE, MANAGEMENT AND COST IN INTERNATIONAL COMPARISON

    Nov 1, 2005, 00:00

  • PMH43 CLINICAL COMPARISON OF SSRIS AND SNRIS IN MAJOR DEPRESSIVE DISORDER- A META-ANALYSIS

    Nov 1, 2005, 00:00

  • PHP42 PAYMENT FOR PHARMACY HANDLING COSTS IN THE HOPD- 2006 REIMBURSEMENT IMPLICATIONS

    Nov 1, 2005, 00:00

  • Economic Burden of Patients with Anemia in Selected Diseases

    Nov 1, 2005, 00:00

  • PSN25 ADULTS WITH ATOPIC DERMATITIS- QUALITY OF LIFE IMPACT

    Nov 1, 2005, 00:00

  • PCN25 INFLUENCE OF THE PORTION OF MEDICAL EXPENSE PAID INDIVIDUALLY ON PHYSICIANS'ATTITUDE TOWARDS CANCER TREATEMENT IN JAPAN

    Nov 1, 2005, 00:00

  • HP7 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN PRIVATE PAYER TRANSPLANT RECIPIENTS

    Nov 1, 2005, 00:00

  • POS3 RISK FOR OSTEOPOROTIC FRACTURES IS REDUCED IN PERSISTENT BISPHOSPHONATE USERS

    Nov 1, 2005, 00:00

  • PNL22 THE SYMPTOMATIC, FUNCTIONAL AND QUALITY OF LIFE IMPACT OF MULTIPLE SCLEROSIS. REPORT ON A QUALITATIVE INVESTIGATION OF THE PATIENTS' PERSPECTIVE

    Nov 1, 2005, 00:00

  • PCV76 COST-EFFECTIVENESS ANALYSIS OF THE USE OF ACETYLSALICYLIC ACID COMPARED TO CLOPIDOGREL IN THE SECONDARY PREVENTION OF PATIENTS WITH PREVIOUS MYOCARDIAL INFRACTION

    Nov 1, 2005, 00:00

  • Brief Reflections on Treatment Satisfaction

    Nov 1, 2005, 00:00

  • PMH26 USING CLAIMS DATA TO ESTIMATE THE ANNUAL PREVALENCE OF SCHIZOPHRENIA IN THE UNITED STATES, 2002

    Nov 1, 2005, 00:00

  • QL5 CLINICAL RESPONSES TO TREATMENT AND CHANGES IN THE DERMATOLOGY LIFE QUALITY INDEX (DLQI) IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB

    Nov 1, 2005, 00:00

  • PCV27 COSTS AND OUTCOMES AFTER FIRST HEART FAILURE HOSPITAL ADMISSION- A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES

    Nov 1, 2005, 00:00

  • PUK23 VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE (KING'S HEALTH QUESTIONNAIRE) IN BRAZILIAN WOMEN WITH URINARY INCONTINENCE

    Nov 1, 2005, 00:00

  • PCV10 DRIVERS OF UNDERUSE OF VITAMIN K ANTAGONISTS IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION IN FRANCE- THE ENSEFAL STUDY

    Nov 1, 2005, 00:00

  • PGI10 COST EFFECTIVENESS OF PROTON PUMP INHIBITOR TRIPLE THERAPY REGIMENS FOR HELICOBACTER PYLORI ERADICATION IN THE PRIMARY CARE SETTING IN IRELAND

    Nov 1, 2005, 00:00

  • POS12 HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND AN INADEQUATE RESPONSE TO ANTI-OSTEOPOROSIS MEDICATION- BASELINE RESULTS OF THE FRENCH COHORT FROM THE OBSERVATIONAL STUDY OF SEVERE OSTEOPOROSIS (OSSO)

    Nov 1, 2005, 00:00

  • PCV8 COST OF HOSPITALIZATION FOR PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN POLAND

    Nov 1, 2005, 00:00

  • PPN6 A UK PHARMACOECONOMIC MODEL OF PARENTERAL PARECOXIB VERSUS OPIOID ANALGESIA FOLLOWING MAJOR SURGERY

    Nov 1, 2005, 00:00

  • PAR20 EFFECTS OF LONG-TERM ADALIMUMAB THERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONGSTANDING, SEVERE RHEUMATOID ARTHRITIS (RA)—RESULTS FROM A 3-YEAR FOLLOW-UP STUDY

    Nov 1, 2005, 00:00

  • POS13 UNDERSTANDING AND ASSESSING TIBIA FRACTURE ON QUALITY OF LIFE; CONCEPTUAL MODELAND NEW DISEASE SPECIFIC HR-QOL MEASURE

    Nov 1, 2005, 00:00

  • PHM5 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA WITH THE NEWLY DEVELOPED HAEMOPHILIA-SPECIFIC INSTRUMENT HAEM-A-QOL

    Nov 1, 2005, 00:00

  • PR1 EVALUATION OF PREFERENCES IN GENITAL HERPES TREATMENT USING A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2005, 00:00

  • MC2 IMPACT OF THE PROPENSITY SCORE ESTIMATION METHOD WHEN MATCHING PATIENTS TO REDUCE RECRUITMENT BIAS IN OBSERVATIONAL STUDIES

    Nov 1, 2005, 00:00

  • PST7 DO PATIENTS WITH ATRIAL FIBRILLATION RECEIVE APPROPRIATE STROKE PREVENTION THERAPY IN PRACTICE?

    Nov 1, 2005, 00:00

  • PGI22 BURDEN OF ILLNESS IS HIGHEST IN PATIENTS WITH SEVERE PAIN SYMPTOMS

    Nov 1, 2005, 00:00

  • PCV74 A BUDGET IMPACT MODEL FOR EPLERENONE IN THE TREATMENT OF HEART FAILURE POST MYOCARDIAL INFARCTION

    Nov 1, 2005, 00:00

  • PCV83 COST-EFFECTIVENESS OF ENDOVASCULARVERSUS CONVENTIONAL ABDOMINAL AORTIC ANEURYSM REPAIR AT ONE YEAR; RESULTS OF A RANDOMIZED TRIAL

    Nov 1, 2005, 00:00

  • PDB8 CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STATIN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS

    Nov 1, 2005, 00:00

  • PHM3 COSTS OF HAEMOPHILIA ASSISTANCE IN ROMANIA

    Nov 1, 2005, 00:00

  • PCN4 COST OF CARE AND ECONOMIC IMPACT OF CETUXIMAB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

    Nov 1, 2005, 00:00

  • PCV7 COSTS OF DIAGNOSIS OF ARRHYTHMOGENIC RIGTH VENTRICULAR CARDIOMYOPATHY IN INDIVIDUALS WITH A FAMILY HISTORY OF THE DISEASE IN POLAND

    Nov 1, 2005, 00:00

  • POS11 AN INTERNATIONAL COMPARISON OF THE IMPACT OF DOSING FREQUENCY ON COMPLIANCE AND PERSISTENCE WITH BISPHOSPHONATE THERAPY, AMONG POST-MENOPAUSAL WOMEN IN THE US, UK AND GERMANY

    Nov 1, 2005, 00:00

  • PMH18 TRANSLATION, GREEK ADAPTATION AND STANDARDIZATION OF THE VERONA SERVICE SATISFACTION SCALE (VSSS-54)- AN INSTRUMENT PATIENTS' SATISFACTION WITH MENTAL HEALTH SERVICES

    Nov 1, 2005, 00:00

  • PO2 DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE TO EVALUATE SEVERITY OF SYMPTOMS IN PATIENTS WITH IBS-C AND IBS-A

    Nov 1, 2005, 00:00

  • PIH5 SENIORS' PHARMACEUTICAL EXPENDITURES IN THE CZECH REPUBLIC

    Nov 1, 2005, 00:00

  • PHP12 PRICING POLICIES FOR THE PHARMACEUTICAL MARKET—AN INTERNATIONAL PERSPECTIVE

    Nov 1, 2005, 00:00

  • PHP11 AN INTRODUCTION TO HEALTH TOURISM AND MEDICAL TOURISM

    Nov 1, 2005, 00:00

  • PCV16 KNOWLEDGE AND USE OF TREATMENT GUIDELINES FOR STROKE PREVENTION OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION (AFIB) IN GERMANY

    Nov 1, 2005, 00:00

  • PHP40 THE IMPACT ON DECISION-MAKING OF CHANGING COST-EFFECTIVENESS OF HEALTH TECHNOLOGIES OVERTIME

    Nov 1, 2005, 00:00

  • POS7 EVALUATION OF DISTRIBUTION OF HIP REPLACEMENT IN HUNGARY ACCORDING TO GEOGRAPHICAL REGIONS AND AGE GROUPS

    Nov 1, 2005, 00:00

  • PCN43 CRITICAL APPRAISAL OF SCIENTIFIC POSTERS COMPARING ANEMIA TREATMENTS IN CANCER PATIENTS- APPLYING ISPORTASK FORCE GUIDELINES ON METHODOLOGICAL QUALITY OF RETROSPECTIVE STUDIES

    Nov 1, 2005, 00:00

  • PIN29 ESTIMATED ANNUAL NHS COSTS OF HUMAN PAPILLOMAVIRUS (HPV) RELATED DISEASES IN THE UK

    Nov 1, 2005, 00:00

  • PHP3 ECONOMIC IMPACT OF A DEVICE FOR PREPARING STERILE SOLUTIONS IN THE MT. SINAI HOSPITAL PHARMACY

    Nov 1, 2005, 00:00

  • PDB25 FIXED COMBINATION METFORMIN PLUS GLIBENCLAMIDE (GLUCOVANCE®) IS COST AND LIFE SAVING COMPARED TO METFORMIN PLUS ROSIGLITAZONE IN TYPE-2 DIABETES PATIENTS IN FRANCE

    Nov 1, 2005, 00:00

  • PMH13 ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS- SF-6D UTILITIES FROM SF-36 SCORES IN A RANDOMISED TRIAL OF ATOMOXETINE

    Nov 1, 2005, 00:00

  • PHP4 ECONOMIC COMPARISON OF TWO XENETIX® 300 PRESENTATIONS

    Nov 1, 2005, 00:00

  • PCV91 COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH FONDAPARINUX TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING UK AND DUTCH ESTIMATES OF COSTS

    Nov 1, 2005, 00:00

  • PCN38 ASSESSING THE IMPACT ON STAFF RESOURCE AND PATIENT WAITING TIME OF A SWITCH FROM IV TO ORAL CHEMOTHERAPY- TIME AND MOTION MODEL FOR HTAS

    Nov 1, 2005, 00:00

  • PIN5 DYNAMIC MODELLING FOR ESTIMATING THE COST-EFFECTIVENESS OF A CHLAMYDIA TRACHOMATIS SCREENING PROGRAM

    Nov 1, 2005, 00:00

  • PCV24 COST-EFFECTIVENESS ANALYSIS OF ALDOSTERONE BLOCKADE WITH EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION (EPHESUS) IN THE FRENCH CONTEXT

    Nov 1, 2005, 00:00

  • PGI5 THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2B (I2KD) PLUS RIBAVIRIN VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC) IN A DEVELOPING COUNTRY—BRAZIL

    Nov 1, 2005, 00:00

  • CV2 COSTS OF CARDIOVASCULAR DISEASE- A CASE-CONTROL STUDY

    Nov 1, 2005, 00:00

  • PIN3 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERONALFA2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC)AND PERSISTENTLY NORMAL ALT LEVELS (PNALT)

    Nov 1, 2005, 00:00

  • In Memoriam- Alan Williams (1928–2005)

    Nov 1, 2005, 00:00

  • PST4 COST-CONSEQUENCE ANALYSIS FOR THE HANDMASTER IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • UB2 QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN CROHN'S DISEASE

    Nov 1, 2005, 00:00

  • PPN9 HEALTH STATUS AS MEASURED BY PATIENT UTILITY DETERMINATION AMONG PATIENTS WITH PAIN- RESULTS FROM A CROSS-SECTIONAL SURVEY

    Nov 1, 2005, 00:00

  • PIN2 ECONOMIC IMPLICATION OF HEPATITIS B VIRAL (HBV) LOAD REDUCTION FOR ENTEVAVIR IN HEPATITIS B E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS

    Nov 1, 2005, 00:00

  • HP5 TREATMENT PATTERNS AMONG POSTMENOPAUSAL OSTEOPOROTIC WOMEN STARTING ON DAILY OR WEEKLY BISPHOSPHONATE THERAPY

    Nov 1, 2005, 00:00

  • Association between the Erectile Dysfunction Inventory of Treatment Satisfaction and the Self-Esteem and Relationship Questionnaire Following Treatment with Sildenafil Citrate for Men with Erectile Dysfunction

    Nov 1, 2005, 00:00

  • PMH19 CHANGES IN NOVEL ANTIPSYCHOTIC USE IN ELDERLY INPATIENTS

    Nov 1, 2005, 00:00

  • PMC2 REVIEW OF THE ACTIVITIES OF THE ISOQOL TRANSLATION AND CULTURAL ADAPTATION (TCA) SPECIAL INTEREST GROUP (SIG)

    Nov 1, 2005, 00:00

  • PCN36 A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCERAFTERANTHRACYCLINE FAILURE

    Nov 1, 2005, 00:00

  • PSU5 FACTORS ASSOCIATED WITH BLOOD TRANSFUSION COSTS DURING AND FOLLOWING SPINAL SURGERY IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PFM3 CROSS-SURVEY OF FRENCH AND PORTUGUESE GENERAL PRACTITIONERS GLOBAL MANAGEMENT OF FIBROMYALGIA

    Nov 1, 2005, 00:00

  • PEY4 EVALUATION OF INCREMENTAL EFFICACY OF LATANOPROST-TIMOLOL IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA USING RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY GLAUCOMA DATABASE

    Nov 1, 2005, 00:00

  • PDB12 BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF ROSIGLITAZONE IN THE TREATMENT OFTYPE-2 DIABETES. THE ITALIAN NHS PERSPECTIVE

    Nov 1, 2005, 00:00

  • PSU6 DIFFERENCES IN BLOOD TRANSFUSION COSTS BY HIP AND KNEE REPLACEMENT AND REVISION SURGERY SUBTYPES

    Nov 1, 2005, 00:00

  • PAR13 THE DIRECT MEDICAL COST OF RHEUMATOID ARTHRITIS IN HONG KONG

    Nov 1, 2005, 00:00

  • PCV3 A PHARMACO-ECONOMIC EVALUATION OF AGGRESSIVE CHOLESTEROL LOWERING AFTER ACUTE CORONARY SYNDROME IN BELGIUM- A SHORT-TERM AND LONG-TERM ASSESSMENT

    Nov 1, 2005, 00:00

  • PCV50 A MULTILEVEL ANALYSIS ON PRESCRIBED STATINES IN A BOLOGNA HEALTH AUTHORITY FROM 2000 TO 2003

    Nov 1, 2005, 00:00

  • HP4 PRIMARY CARE AND GATEKEEPER MODELS IN GERMANY — WHAT DO THE PATIENTS WANT?

    Nov 1, 2005, 00:00

  • PMH16 EFFECT OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) ON COST OF CARE IN THE CANADIAN OUTCOMES STUDY IN DEMENTIA

    Nov 1, 2005, 00:00

  • PEY8 EYE ADVERSE EFFECTS ASSOCIATED WITH POLYVINYL ALCOHOL TEAR DROPS AFTER LASER ASSISTED SUBEPITHELIAL KERATECTOMY (LASEK)

    Nov 1, 2005, 00:00

  • PCV41 PORTUGUESE ACTIVE POPULATION HEALTH RELATED QUALITY OF LIFE RESULTS USING THE SF-6D

    Nov 1, 2005, 00:00

  • UH1 COST AND QUALITY OF LIFE OF HEMOPHILIA- COMPARISON BETWEEN PATIENTS WITH AND PATIENTS WITHOUT INHIBITORS

    Nov 1, 2005, 00:00

  • PDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES- LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN

    Nov 1, 2005, 00:00

  • MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS

    Nov 1, 2005, 00:00

  • PCN7 COST ANALYSIS OF 3-YEARS FOLLOW-UP OF A TRASTUZUMAB TREATED COHORT

    Nov 1, 2005, 00:00

  • PEY19 METHODS FOR A POPULATION-BASED INTERNATIONAL STUDY ON THE BURDEN OF ILLNESS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2005, 00:00

  • PDB34 DIABETES PREVALENCE AND DIRECT MEDICAL COST ANALYSIS PER YEAR FROM 1997 TO 2001 IN TAIWAN

    Nov 1, 2005, 00:00

  • PNL17 A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE) WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND

    Nov 1, 2005, 00:00

  • PED1 USING EQ-5DTO DERIVE UTILITIES FORTHE QUALITY OF LIFE-ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA)

    Nov 1, 2005, 00:00

  • PMH10 A MODELLED ECONOMIC EVALUATION COMPARING ATOMOXETINEWITH CURRENT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PCV47 ROSUVASTATIN 40MG VERSUS ATORVASTATIN 80MG IN HIGH-RISK PATIENTS WITH HYPERCHOLESTEROLAEMIA- ECONOMIC ANALYSIS OF THE POLARIS STUDY

    Nov 1, 2005, 00:00

  • PSN23 FACTORS INFLUENCING QUALITY OF LIFE IN ATOPIC DERMATITIS

    Nov 1, 2005, 00:00

  • PUK18 ESTIMATION AND ANALYSIS OF DIRECT MEDICAL COST OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN DIALYSIS PATIENTS

    Nov 1, 2005, 00:00

  • PIN23 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE UK

    Nov 1, 2005, 00:00

  • PAS3 ASTHMA CONTROL IN SPAIN. DOES TREATMENT PROFILE AND SEASON MATTER?

    Nov 1, 2005, 00:00

  • PAS4 THE COST OF ASTHMA EXACERBATIONS OF DIFFERENT SEVERITY LEVELS

    Nov 1, 2005, 00:00

  • PDB61 PERCEIVED HEALTH CARE INFORMATION ON DIABETES- MEASUREMENT OF PATIENT SATISFACTION

    Nov 1, 2005, 00:00

  • PUK32 VALIDATION OF THE INTERNATIONAL PROSTATE SYMPTOMS SCORE IN ITALIAN WOMEN WITH LUTS.THE FLOW STUDY

    Nov 1, 2005, 00:00

  • PST8 WARFARIN PATIENT SEGMENTS- GENERAL PRACTITIONERS VERSUS SPECIALISTS

    Nov 1, 2005, 00:00

  • PCV37 USE OF TIME-STAMPED HOSPITAL DATA TO EXAMINE CARE PATTERNS OF ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2005, 00:00

  • PCV69 COST-EFFECTIVENESS OF ADD-ON THERAPY WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND PERSISTENTLY LOW HDL-C IN THE UK AND GERMANY

    Nov 1, 2005, 00:00

  • PMC5 A STANDARD SET OF UNIT COSTS FOR GERMANY

    Nov 1, 2005, 00:00

  • PMH33 FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2005, 00:00

  • PHP23 A COMPARATIVE ANALYSIS OF THE FINANCING, PRICING AND REIMBURSEMENT SYSTEMS FOR PRESCRIPTION DRUGS IN THE NORDIC COUNTRIES

    Nov 1, 2005, 00:00

  • PHP37 PHARMACOECONOMIC CLAIMS IN PRESCRIPTION DRUG ADVERTISEMENTS IN FINNISH MEDICAL JOURNALS

    Nov 1, 2005, 00:00

  • PPN1 COGNITIVE FUNCTION IMPAIRMENT IN PATIENTS WITH NEUROPATHIC PAIN

    Nov 1, 2005, 00:00

  • POB5 AN ANALYSIS OF THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS

    Nov 1, 2005, 00:00

  • POS6 IMPACT OF BISPHOSPHONATES ON OSTEOPOROTIC FRACTURES, PATIENT QUALITY OF LIFE AND TREATMENT COSTS-THE CASE OF GERMANY

    Nov 1, 2005, 00:00

  • PRS15 OUTCOMES, RESOURCE CONSUMPTION AND COSTS OF INTENSIVE CARE PATIENTS HOSPITALIZED WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN THE USA AND CANADA

    Nov 1, 2005, 00:00

  • PCN11 ECONOMIC EVALUATION OF BORTEZOMIB IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS IN CANADA

    Nov 1, 2005, 00:00

  • PST13 EFFECTIVENESS OF AN EARLY REHABILITATION STRATEGY WITH HOME FOLLOW-UP FOR PATIENTS WITH ISCHEMIC VASCULAR CEREBRAL DISEASE IN MEXICO

    Nov 1, 2005, 00:00

  • POS8 CONTENT VALIDATION OF OSTEOPOROSIS TREATMENT PREFERENCE QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • CN1 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANY

    Nov 1, 2005, 00:00

  • PMH31 12 MONTH COST-UTILITY ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY

    Nov 1, 2005, 00:00

  • PCV5 COST-EFFECTIVENESS OF DRUG ELUTING STENTS FOR STABLE ANGINA

    Nov 1, 2005, 00:00

  • PMH1 COST EFFECTIVENESS OF ESCITALOPRAM IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)

    Nov 1, 2005, 00:00

  • PMH7 THE BAD STUDY- SOCIAL AND ECONOMIC BURDEN OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD) IN ITALY

    Nov 1, 2005, 00:00

  • CO1 VALIDATION OF DIAGNOSTIC PROCEDURES IN SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA CONCORDANCE BETWEEN INITIAL AND FINAL DIAGNOSIS IN DAILY CLINICAL PRACTICE

    Nov 1, 2005, 00:00

  • PCN22 COSTS OF COMMON TREATMENT OPTIONS FOR INDOLENT FOLLICULAR NON-HODGKIN'S LYMPHOMA

    Nov 1, 2005, 00:00

  • PCN37 IMPACT OF HEALTH CARE REFORMSAND CHANGING PAYMENT MECHANISMS ON HEALTH ECONOMIC EVALUATIONS IN GERMANY

    Nov 1, 2005, 00:00

  • PUK16 BPH AND IPSS SCORES EVALUATED AFTER 6 MONTHS ACCORDING TO THE TYPE OF DISEASE MANAGEMENT

    Nov 1, 2005, 00:00

  • PCN31 COST EFFECTIVENESS MODEL OF IV BISPHOSPHONATES IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES- A GERMAN INPATIENT PERSPECTIVE

    Nov 1, 2005, 00:00

  • PDB15 A MODEL BASED ANALYSIS OF COSTS AND EFFECTIVENESS OF CHIROPODIST CARE IN DIABETEC PATIENTS

    Nov 1, 2005, 00:00

  • PRS2 PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION

    Nov 1, 2005, 00:00

  • PNL19 META-ANALYSIS OF CASE SERIES TO PROVIDE INPUTS FOR A DISCRETE EVENT SIMULATION OF DEEP BRAIN STIMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE

    Nov 1, 2005, 00:00

  • PGI12 THE COSTS OF ACUTE-ON-CHRONIC LIVER FAILURE—A BOTTOM-UP ANALYSIS BASED ON INDIVIDUAL PATIENT DATA

    Nov 1, 2005, 00:00

  • PNL10 THE COSTS OF INFORMAL CARE IN NEUROLOGICAL DISORDERS IN SPAIN

    Nov 1, 2005, 00:00

  • PCV56 EVALUATION OF COSTS RELATED TO HYPERTENSION IN PATIENTS WITH CONCOMITANT DISEASES IN POLAND

    Nov 1, 2005, 00:00

  • PDB59 DEVELOPMENT OF A SCALE FOR DIABETIC PATIENT PROFILING BASED ON PATIENT ATTITUDE TOWARDS INSULIN

    Nov 1, 2005, 00:00

  • PMC8 ESTIMATING COSTS AT THE FAMILY LEVEL

    Nov 1, 2005, 00:00

  • CN3 HEALTH ECONOMIC EVALUATION BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

    Nov 1, 2005, 00:00

  • PST2 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH- AN ECONOMIC EVALUATION FOR THE NETHERLANDS BASED ON THE LIFE-STUDY

    Nov 1, 2005, 00:00

  • HP8 PATIENT CHARACTERICS, GLYCEMIC CONTROL, AND THE USE OF ANTIDIABETIC AGENTS AMONG INDIVIDUALS DIAGNOSED WITH TYPE-2 DIABETES- EVIDENCE FROM THE UK

    Nov 1, 2005, 00:00

  • PIN19 INCORPORATING COMPLIANCE RATES INTO THE COST OF TREATING HIV/AIDS IN TWO AFRICAN COUNTRIES

    Nov 1, 2005, 00:00

  • PCV81 DISCRETE EVENT SIMULATION OF LONG-TERM HEALTH BENEFITS AND COST-EFFECTIVENESS OF IMPLANTING DUAL CHAMBERVS. SINGLE CHAMBER VENTRICULAR PACEMAKERS IN ITALY

    Nov 1, 2005, 00:00

  • PDB27 COST-EFFECTIVENESS OFACARBOSE IN ADDITION TO EXISTING TREATMENTS IN TYPE-2 DIABETES IN GERMANY

    Nov 1, 2005, 00:00

  • UH4 CHARACTERISTICS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH OVERACTIVE BLADDER- RESULTS FROM THE MATRIX STUDY

    Nov 1, 2005, 00:00

  • PCV39 THE EFFECT OF GENDER ON HEALTH-RELATED QUALITY OF LIFE AFTER CORONARY STENT IMPLANTATION

    Nov 1, 2005, 00:00

  • PHP28 ECONOMIC EVALUATION OF NEWTECHNOLOGIES IN THE HOSPITAL SETTING- THE EXPERIENCE OFTHEAZIENDA OSPEDALIERA Dl VERONA, ITALY

    Nov 1, 2005, 00:00

  • PUK33 DEVELOPMENT AND TESTING OF A COMPOSITE SCALE TO ASSESS THERAPEUTIC RESPONSE IN STRESS URINARY INCONTINENCE

    Nov 1, 2005, 00:00

  • CV4 DISCRETE EVENT SIMULATION OF THE ECONOMIC CONSEQUENCES OF ADDING MANAGED VENTRICULAR PACING MODE (DDDR-MVP) TO A STANDARD DUAL CHAMBER PACEMAKER (DDDR) IN FRANCE

    Nov 1, 2005, 00:00

  • PMH24 GEO OBSERVATIONAL STUDY- 24 MONTHS CHARACTERISTICS OF SOCIOECONOMIC AND CLINICAL STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

    Nov 1, 2005, 00:00

  • PAS2 FLUTICASONE PROPIONATE/SALMETEROL COMBINATION IMPROVES HEALTH OUTCOMES AND QUALITY OF LIFE IN CHILDREN WITH POORLY CONTROLLED ASTHMA IN IRELAND

    Nov 1, 2005, 00:00

  • IN2 ASSESSEMENT OF THE ADDITIONAL COST OF DROTRECOGIN ALFA (ACTIVATED) RELATIVE TO STANDARD CARE IN THE TREATMENT OF SEVERE SEPSIS IN A MULTICENTIC OBSERVATIONAL STUDY IN FRANCE

    Nov 1, 2005, 00:00

  • PUK20 BENIGN PROSTATE HYPERPLASIA- MUST BOTHERSOMENESS OF SYMPTOMS BE PRIVILEGED?

    Nov 1, 2005, 00:00

  • An Economic Evaluation of Triptan Products for Migraine

    Nov 1, 2005, 00:00

  • PRS13 COST ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION DURING TREATMENT FOR RESPIRATORY TRACK INFECTIONS (RTIS) WITH TELITHROMYCIN OR CLARITHROMYCIN OR AMOXICILLIN/CLAVULANIC ACID IN GREECE

    Nov 1, 2005, 00:00

  • PSN2 COST-EFFECTIVENESS ANALYSIS- ALDARA™ (IMIQUIMOD) CREAM, 5% IN THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA IN NORWAY

    Nov 1, 2005, 00:00

  • PO1 TRAJECTORIES OF EQ-5D QUALITY OF LIFE UTILITY SCORES FOR 10,000 SCHIZOPHRENIA OUTPATIENTS OVER 2 YEARS- A REPORT FROM THE SOHO STUDY

    Nov 1, 2005, 00:00

  • POB7 COSTS AND HEALTH CARE CONSUMPTIONS IN THE ABDOMINALLY OBESE POPULATION

    Nov 1, 2005, 00:00

  • PMC6 AFFORDABLE BOOTSTRAPS? EVALUATING FREEWARE OPTIONS FORANALYZING INCREMENTAL COST EFFECTIVENESS DATA

    Nov 1, 2005, 00:00

  • PCV87 VITAE THROMBOSIS STUDY- THE PREVALENCE AND BURDEN OF VENOUS THROMBOEMBOLIC DISEASE (VTE) IN EUROPE

    Nov 1, 2005, 00:00

  • PRS21 PATIENT SATISFACTION WITH TREATMENT FOR COPD

    Nov 1, 2005, 00:00

  • PSN4 COST-EFFECTIVENESS MODEL OFALDARA™ (IMIQUIMOD) CREAM, 5% IN SUPERFICIAL BASAL CELL CARCINOMA IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PCN29 PER-PATIENT COST OF HOSPITAL CARE FOR ADVANCED BREAST CANCER IN THE UK BASED ON A PATIENT-LEVEL RESOURCE UTILISATION DATASET

    Nov 1, 2005, 00:00

  • PDB23 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NPH-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN GERMANY

    Nov 1, 2005, 00:00

  • PSN18 ATOPIC DERMATITIS- IMPACT ON SEXUALITY

    Nov 1, 2005, 00:00

  • PCV82 COST-UTILITY OF CILOSTAZOL FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN SCOTLAND

    Nov 1, 2005, 00:00

  • PCN30 COMPARATIVE ANALYSIS OF DRUG COST OF BREAST, CERVICAL AND COLORECTAL CANCER IN HUNGARY

    Nov 1, 2005, 00:00

  • PHP47 EVALUATION OF THE RELATIONSHIP BETWEEN PHARMACEUTICAL PRODUCT PRICE AND HEALTH-RELATED QUALITY OF LIFE USING WHOLESALE ACQUSITION COST AND AVERAGE EFFECT SIZE

    Nov 1, 2005, 00:00

  • PMH3 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GROWN-UPS- ADMINISTRATIVE DATA ON CO-EXISTING CONDITIONS

    Nov 1, 2005, 00:00

  • PHM8 THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON OVERLOAD (IO)

    Nov 1, 2005, 00:00

  • PUK13 COST-MINIMISATION-ANALYSIS ON THE TREATMENT OF URINARY INCONTINENCE WITH TROSPIUM CHLORIDE IN COMPARISON WITH OXYBUTYNIN IN GERMANY

    Nov 1, 2005, 00:00

  • PEY22 DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE PAINFUL SYMPTOM CHECKLIST ALLOWING PROVIDING A COMPLETE DESCRIPTION OF PAIN IN OPHTHALMIC DISEASES

    Nov 1, 2005, 00:00

  • PIN13 SYSTEMATIC REVIEW ON THE SHARE OF ANTIBIOTIC THERAPY COST IN RELATION OVERALL DIRECTTREAMENT COSTS OF MOST FREQUENT NOSOCOMIAL AND COMMUNITY ACQUIRED INFECTIONS IN ADULTS

    Nov 1, 2005, 00:00

  • PDB13 THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS

    Nov 1, 2005, 00:00

  • PAR15 TARGETED ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA- EARLY ANALYSIS FROM A QUALITATIVE STUDY

    Nov 1, 2005, 00:00

  • PCN3 POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN HIGHLY EMETOGENIC CISPLATINE-BASED CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • PCV51 PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN 10/20MG) IN SPAIN

    Nov 1, 2005, 00:00

  • PDB41 DIABETIC PERIPHERAL NEUROPATHY- EVALUATION OF THE ASSOCIATION BETWEEN NEUROPATHIC SYMPTOMS (NTSS-6-SA)AND HEALTH CARE RESOURCE USE AND PRODUCTIVE LOSSES

    Nov 1, 2005, 00:00

  • PMH37 THE ECONOMIC BURDEN OF SCHIZOPHRENIA IN THE UNITED STATES IN 2002

    Nov 1, 2005, 00:00

  • PAR14 EVALUATION OF ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA USING NATIONAL CLAIMS DATA

    Nov 1, 2005, 00:00

  • PMH40 LONG-TERM MAINTENANCE OF INITIAL HEALTH RELATED QUALITY OF LIFE (HRQL) IMPROVEMENTS GAINED THROUGH ANTIPSYCHOTIC TREATMENT- 24-MONTH RESULTS FROM THE SCHIZOPHRENIA HEALTH OUTCOMES (SOHO) STUDY

    Nov 1, 2005, 00:00

  • PMH22 HOSPITALIZATION AND MEDICATION USE IN SCHIZOPHRENIA PATIENTS RECEIVING RISPERIDONE LONG-ACTING INJECTABLE OR ORAL ATYPICAL ANTIPSYCHOTIC MEDICATION

    Nov 1, 2005, 00:00

  • PCV88 TREATMENT PATTERN, RESOURCE UTILIZATION AND COSTS OF INPATIENTTHROMBOPROPHYLAXIS IN POLAND

    Nov 1, 2005, 00:00

  • PGI6 ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH PANTOPRAZOLE IN THE ACUTE AND MAINTENANCE TREATMENT OF REFLUX ESOPHAGITIS IN FINLAND

    Nov 1, 2005, 00:00

  • PEY10 COMBIGAN—COST-MINIMIZATION ANALYSIS OF BRIMONIDINE/TIMOLOL FIXED COMBINATION IN THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA

    Nov 1, 2005, 00:00

  • PGI20 ECONOMIC VALUATION MODELING FOR ASSESSING BIOTECHNOLOGY/PHARMACEUTICAL DEVELOPMENTAL OPPORTUNITIES

    Nov 1, 2005, 00:00

  • PHP35 AGE AND GENDER IN PHARMACEUTICAL EXPENDITURE- ATOOL FOR RISK CALCULATION

    Nov 1, 2005, 00:00

  • PCV20 PHARMACOTHERAPY AND OUTCOMES AMONG VETERANS WITH CHRONIC HEART FAILURE (2000-2002)

    Nov 1, 2005, 00:00

  • PMC28 ITEM RESPONSE BIAS IN INSTRUMENTAL ACTIVITY DAILY LIVING SCALE IN ASIAN OLDER ADULTS

    Nov 1, 2005, 00:00

  • PIN28 RESOURCE USE AND COSTS ASSOCIATED WITH THE MANAGEMENT OF PAP III, PAP MID AND PAP IV IN THE PRE-HPVVACCINE ERA IN GERMANY

    Nov 1, 2005, 00:00

  • PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER- COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN ...

    Nov 1, 2005, 00:00

  • PHM1 COST-EFFECTIVENESS OF REGULAR CONTINUOUS PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA A

    Nov 1, 2005, 00:00

  • PHP38 BELIEFS ABOUT MEDICINES AMONG SWEDISH PHARMACY EMPLOYEES

    Nov 1, 2005, 00:00

  • PAR8 COST COMPARISON OF THE COMBINATION TRAMADOL PLUS PARACETAMOL VERSUS NSAIDS PLUS PROTON PUMP INHIBITORS IN THE TREATMENT OF OSTEOARTHRITIS IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PAR5 OSTEOARTHRITIS-CHONDROITIN SULFATE LONG TERM UTILIZATION REDUCES CONSUMPTION OF COXIBS, NSAIDS ANALGESICS

    Nov 1, 2005, 00:00

  • PCV11 ANTICOAGULATION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION- AN EVALUATION OF STABILITY AND EARLY FACTORS THAT PREDICT LONGER-TERM STABILITY ON WARFARIN IN A LARGE UK POPULATION

    Nov 1, 2005, 00:00

  • PAR12 IMPROVEMENT IN HEALTH UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH ADALIMUMAB (HUMIRA®)

    Nov 1, 2005, 00:00

  • PSN16 NAIL PSORIASIS- IMPACT ON QUALITY OF LIFE

    Nov 1, 2005, 00:00

  • PDB1 DIABETIC PERIPHERAL NEUROPATHY- EVALUATION OF THE INTER-ASSOCIATION BETWEEN THE RANGES OF NEUROPATHIC SYMPTOMS

    Nov 1, 2005, 00:00

  • CO2 EARLY GLYCEMIC CONTROL IMPROVES HEALTH AND ECONOMIC BENEFITS IN TYPE 2 DIABETES- A MODEL BASED ANALYSIS

    Nov 1, 2005, 00:00

  • PCN5 THE COST OF SECOND-LINE TREATMENT OF OVARIAN CANCER IN POLISH SETTINGS

    Nov 1, 2005, 00:00

  • PCN6 POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)

    Nov 1, 2005, 00:00

  • PST5 COST AND OUTCOMES AFTER FIRST STOKE HOSPITAL ADMISSION- A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES

    Nov 1, 2005, 00:00

  • PIH13 ASSESSING THE PSYCHOMETRIC PROPERTIES OF THE PSYCHOSOCIAL SUBSCALE OF THE MENOPAUSE-SPECIFIC QUALIPAUSE INVENTORY (QPI)WITH ITEM RESPONSE THEORY

    Nov 1, 2005, 00:00

  • PRS9 COST OF COMMUNITY ACQUIRED PNEUMONIA (CAP) TREATMENT WITH KETEK (TELITHROMYCIN) VS CLARITHROMYCIN FROM PUBLIC PAYER PERSPECTIVE IN POLAND

    Nov 1, 2005, 00:00

  • PCV58 COST-EFFECTIVENESS OF INDAPAMIDE IN PATIENTS WITH MILD-TO-MODERATE HYPERTENSION

    Nov 1, 2005, 00:00

  • PDB9 PROJECTED IMPACT ON CORONARY HEART DISEASE AT 5, 10 AND 35 YEARS OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PUK30 BENIGN PROSTATE HYPERPLASIA- RELATION BETWEEN IPSS, SPI AND QUALITY OF LIFE IPSS ITEM SCORES

    Nov 1, 2005, 00:00

  • PHM9 HOW PATIENTS WITH HAEMOPHILIA ARE SATISFIED WITH THEIR TREATMENT

    Nov 1, 2005, 00:00

  • PHP44 COST AVOIDANCE OF CLINICAL PHARMACIST INTERVENTIONS AT A UNIVERSITYTEACHING HOSPITAL

    Nov 1, 2005, 00:00

  • PCN41 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ADVANCED COLORECTAL CANCER (ACC)- “CCRA-QOL”

    Nov 1, 2005, 00:00

  • PHP46 DEFINING COMPLIANCE/ADHERENCE AND PERSISTENCE- ISPOR SPECIAL INTEREST WORKING GROUP

    Nov 1, 2005, 00:00

  • PMC24 USE OF PHARMACOECONOMICS/HEALTH ECONOMIC TOOL (PE/HE) IN LOCAL HEALTH CARE DECISION MAKING (DM)

    Nov 1, 2005, 00:00

  • PIH3 ESTIMATING A PREFERENCE-BASED MEASURE OF SOCIAL PARTICIPATION FROM THE HANDICAP SCALE FOR CHILDREN

    Nov 1, 2005, 00:00

  • PCV9 THE EFFECT OF ANTICOAGULATION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION-COMPARING EFFICACY AND EFFECTIVENESS

    Nov 1, 2005, 00:00

  • QL1 DETERMINING THE MINIMALLY IMPORTANT DIFFERENCE OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q)

    Nov 1, 2005, 00:00

  • PRS10 PROJECTING THE FUTURE COSTS OF ASTHMA AND COPD IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PNL14 USE OF THE SELF-ADMINISTERED NEUROPATHY TOTAL SYMPTOM SCORE—6 (NTSS-6 SA) IN AN INTERNATIONAL STUDY

    Nov 1, 2005, 00:00

  • PSN6 COST-EFFECTIVENESS OF BRIVUDINE COMPARED TO ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN GERMANY

    Nov 1, 2005, 00:00

  • PCV26 COST-EFFECTIVENESS OF CANDESARTAN IN GERMANY FOR PATIENTS WITH CHRONIC HEART FAILURE

    Nov 1, 2005, 00:00

  • PMH25 EFFECTIVENESS AND TOLERABILITY OUTCOMES OF RISPERIDONE LONG-ACTING INJECTION COMPARED TO CONVENTIONAL DEPOT ANTIPSYCHOTICS IN A LARGE CANADIAN PSYCHIATRIC HOSPITAL

    Nov 1, 2005, 00:00

  • PSU4 TOTAL INSURANCE COST OF TREATMENT OF HIP FRACTURES ACCORDING TO THE LOAD STABILITY OF DIFFERENT SURGICAL METHODS

    Nov 1, 2005, 00:00

  • PCN46 WHAT ARE THE PSYCHOSOCIAL CONSEQUENCES OF AN ABNORMAL SCREENING-MAMMOGRAPHY?

    Nov 1, 2005, 00:00

  • PIN10 ANTIMICROBIAL TREATMENT OF ACUTE OTITIS MEDIA AND ITS PHARMACOECONOMIC ANALYSIS IN SLOVAKIA

    Nov 1, 2005, 00:00

  • PNL21 THE COST OF MULTIPLE SCLEROSIS (MS) IN EUROPE

    Nov 1, 2005, 00:00

  • IC1 THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS BASED ON THE A SYNTHESIS OF THE RESULTS OF I 5 RANDOMISED CONTROLLED TRIALS

    Nov 1, 2005, 00:00

  • PCV90 COST EFFECTIVENESS OF FONDAPARINUX COMPARED WITH ENOXAPARIN FOR EXTENDED PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING DUTCH ESTIMATES OF COSTS

    Nov 1, 2005, 00:00

  • PCV18 WHEN SHOULD PATIENTS BE SWITCHED FROMVKATO NEW TREATMENT- DEVELOPMENT AND PILOT TESTING OF A SELF-REPORTED QUESTIONNAIRE TO TARGET PATIENTS WHO WOULD BENEFIT MOST

    Nov 1, 2005, 00:00

  • POB6 MODIFICATION OF LIFE STYLE AND OBESITY MANAGEMENT IN PRIMARY CARE

    Nov 1, 2005, 00:00

  • PEY6 A PUBLIC HEALTH IMPACT MODEL OF ANECORTAVE ACETATE IN WET AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2005, 00:00

  • PMH36 CASE STUDY OF PATTERN MIXTURE APPROACH FOR COMBINING COMPLETION RATESAND EFFICACY FOR CLINCALLY MEANINGFULL OUTCOMES IN SCHIZOPHRENIA DRUG TRIALS

    Nov 1, 2005, 00:00

  • PMH42 COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE- A NATURALISTIC STUDY

    Nov 1, 2005, 00:00

  • PDB42 IMPROVING DIABETES CARE MANAGEMENT ACROSS A SET OF COMPREHENSIVE MEASURES IN A MEDICAID MANAGED CARE ORGANIZATION

    Nov 1, 2005, 00:00

  • PCN14 COST-EFFECTIVENESS ANALYSIS OF ARANESP® (DARBEPOETIN ALFA) ADMINISTERED ONCE EVERY THREE WEEKS COMPARED TO ONCE EVERY WEEK

    Nov 1, 2005, 00:00

  • PAS6 CLINICAL OUTCOME OF CHRONIC ASTHMA

    Nov 1, 2005, 00:00

  • PCV35 HOSPITALIZATIONS FOR CARDIOVASCULAR EVENTS- FRENCH DRG ANALYSIS

    Nov 1, 2005, 00:00

  • PPN3 BURDEN OF ILLNESS OF PATIENTS WITH NEUROPATHIC PAIN IN PRIMARY CARE IN THE UK

    Nov 1, 2005, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160 (current)
  • »